Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This study is currently recruiting participants.
Study NCT00538850 Information provided by National Cancer Institute (NCI)
First Received: October 1, 2007 Last Updated: July 15, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Additional conditions recognized in this trial
Lymphoma, Large-Cell, Immunoblastic
Lymphoma, Non-Hodgkin
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Interventions listed in this trial
fentanyl sublingual spray
questionnaire administration
Additional drug interventions recognized in this trial
Fentanyl
More general drug interventions related to this trial
Adjuvants, Anesthesia
Analgesics
Analgesics, Opioid
Anesthetics
Anesthetics, General
Anesthetics, Intravenous
Central Nervous System Agents
Central Nervous System Depressants
Narcotics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Insys Therapeutics Inc
Back to top of Main Content
